ATE200030T1 - Pegylationsverfahren - Google Patents

Pegylationsverfahren

Info

Publication number
ATE200030T1
ATE200030T1 AT98901405T AT98901405T ATE200030T1 AT E200030 T1 ATE200030 T1 AT E200030T1 AT 98901405 T AT98901405 T AT 98901405T AT 98901405 T AT98901405 T AT 98901405T AT E200030 T1 ATE200030 T1 AT E200030T1
Authority
AT
Austria
Prior art keywords
substrate
pegylation
peg
attachment
reaction
Prior art date
Application number
AT98901405T
Other languages
English (en)
Inventor
Gillian Elizabeth Francis
Derek Fisher
Farooq Malik
Original Assignee
Polymasc Pharmaceuticals Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9701804.8A external-priority patent/GB9701804D0/en
Priority claimed from GBGB9701800.6A external-priority patent/GB9701800D0/en
Priority claimed from GBGB9704653.6A external-priority patent/GB9704653D0/en
Priority claimed from GBGB9708055.0A external-priority patent/GB9708055D0/en
Application filed by Polymasc Pharmaceuticals Plc filed Critical Polymasc Pharmaceuticals Plc
Application granted granted Critical
Publication of ATE200030T1 publication Critical patent/ATE200030T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • External Artificial Organs (AREA)
AT98901405T 1997-01-29 1998-01-28 Pegylationsverfahren ATE200030T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9701804.8A GB9701804D0 (en) 1997-01-29 1997-01-29 Pegylation process
GBGB9701800.6A GB9701800D0 (en) 1997-01-29 1997-01-29 Pegylation process
GBGB9704653.6A GB9704653D0 (en) 1997-03-06 1997-03-06 Pegylation process
GBGB9708055.0A GB9708055D0 (en) 1997-04-22 1997-04-22 Pegylation process
PCT/GB1998/000253 WO1998032466A1 (en) 1997-01-29 1998-01-28 Pegylation process

Publications (1)

Publication Number Publication Date
ATE200030T1 true ATE200030T1 (de) 2001-04-15

Family

ID=27451595

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98901405T ATE200030T1 (de) 1997-01-29 1998-01-28 Pegylationsverfahren

Country Status (6)

Country Link
EP (1) EP0921817B1 (de)
JP (1) JP2001508783A (de)
AT (1) ATE200030T1 (de)
AU (1) AU5773798A (de)
DE (1) DE69800640T2 (de)
WO (1) WO1998032466A1 (de)

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US8007784B1 (en) 1996-06-27 2011-08-30 Albany Medical College Antigenic modulation of cells
US6548263B1 (en) 1997-05-29 2003-04-15 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
AU7987898A (en) * 1997-06-26 1999-01-19 Albany Medical College Antigenic modulation of viral particules
AU9402198A (en) * 1997-09-26 1999-04-23 Becton Dickinson & Company Preparing conjugates using polyethylene glycol linkers
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
WO1999043357A1 (en) * 1998-02-25 1999-09-02 Micrologix Biotech Inc. Indolicidin and cationic peptides conjugated with polymers
ATE275422T1 (de) * 1998-04-28 2004-09-15 Applied Research Systems Konjugate aus polyole und beta-interferon
AU4253799A (en) * 1998-06-12 2000-01-05 Micrologix Biotech, Inc. Cancer therapy with cationic peptides
MXPA01003790A (es) 1998-10-16 2002-09-18 Biogen Inc Proteinas de fusion beta - interferon y sus usos.
SG110047A1 (en) 1998-10-16 2005-04-28 Biogen Inc Polymer conjugates of interferon beta-a1 and uses
EP1144452B1 (de) * 1998-11-03 2006-01-11 Centocor, Inc. Modifizierte antikörper und antikörper-fragmente mit verlängerter aktivitätsdauer
EP1135493A2 (de) * 1998-11-30 2001-09-26 Eli Lilly And Company Erythropoietische substanzen
MXPA01007777A (es) 1999-02-01 2003-10-06 Eidgenoess Tech Hochschule Bio-materiales formadas por reaccion de adicion nucleofila a grupos insaturados conjugados.
US6958212B1 (en) 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
IL150153A0 (en) 2000-01-10 2002-12-01 Maxygen Holdings Ltd G-csf conjugates
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1276856A4 (de) 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusionsproteine
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
ATE541587T1 (de) * 2000-06-02 2012-02-15 Eidgenoess Tech Hochschule Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen
CN1434726A (zh) 2000-06-08 2003-08-06 拉卓拉药物公司 包含高分子量聚环氧乙烷的多价平台分子
EP1294949A4 (de) 2000-06-15 2004-08-25 Human Genome Sciences Inc Menschlicher tumornekrosefaktor delta und epsilon
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
EP1674477B1 (de) 2000-08-18 2009-12-09 Dyax Corp. Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
DE60137525D1 (de) * 2000-10-16 2009-03-12 Chugai Pharmaceutical Co Ltd Peg-modifiziertes erythropoietin
CA2426692C (en) 2000-10-19 2011-01-25 Eidgenossische Technische Hochschule Zurich Block copolymers for multifunctional self-assembled systems
EP1345628B1 (de) 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
CN100528235C (zh) * 2000-12-20 2009-08-19 霍夫曼-拉罗奇有限公司 红细胞生成素共轭物
DE10102878A1 (de) * 2001-01-23 2002-08-01 Haemosys Gmbh Oligo- oder Polyalkylengekoppelte Thrombininhibitoren
EP1366075B1 (de) 2001-02-27 2009-05-27 Maxygen Aps Neue interferon-beta-ähnliche moleküle
KR20030085041A (ko) * 2001-03-22 2003-11-01 노보 노르디스크 헬스 케어 악티엔게젤샤프트 응고 인자 ⅶ 유도체
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
MY137181A (en) 2001-05-21 2009-01-30 Nektar Therapeutics Pulmonary administration of chemically modified insulin
CA2446723C (en) 2001-05-25 2014-01-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
HU228621B1 (en) 2001-09-24 2013-04-29 Univ Oregon Health & Science Modification of feeding behavior
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
CA2472882A1 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
GEP20074024B (en) 2002-01-18 2007-01-10 Biogen Idec Inc Polyalkylene glycol comprising a radical for conjugation of biologically active compound
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
WO2003082926A2 (en) * 2002-03-26 2003-10-09 Biosynexus Incorporated Antimicrobial polymer conjugates
PL373728A1 (en) 2002-04-30 2005-09-05 Maxygen Holdings Ltd. Factor vii or viia polypeptide variants
PL211175B1 (pl) 2002-06-21 2012-04-30 Novo Nordisk Healthcare Ag Koniugat polipeptydu czynnika VII, sposób wytwarzania takiego koniugatu, zawierający taki koniugat preparat farmaceutyczny oraz zastosowanie takiego koniugatu
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EP1681303B1 (de) * 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylierte Polypeptide, besonders HASyliertes Erythropoietin
ATE409048T1 (de) 2002-10-08 2008-10-15 Fresenius Kabi De Gmbh Pharmazeutisch aktive oligosaccharid-conjugate
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
ES2386010T3 (es) 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
EP2055189A1 (de) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylierungsverfahren und durch die Verfahren hergestellte Proteine/Peptide
DE602004013769D1 (de) * 2003-04-15 2008-06-26 Opperbas Holding Bv Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
NZ544728A (en) 2003-06-19 2009-04-30 Bayer Healthcare Llc Factor VII or VIIa Gla domain variants
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP2263684A1 (de) 2003-10-10 2010-12-22 Novo Nordisk A/S IL-21 Derivate
EP2641611A3 (de) 2003-10-17 2013-12-18 Novo Nordisk A/S Kombinationstherapie
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
DK1696947T3 (en) 2003-12-19 2014-03-17 Hoffmann La Roche APPLICATION OF ERYTHROPOIETIN IN THE TREATMENT OF DISORDERS OF THE IRON DISTRIBUTION IN CHRONIC INFLAMMATORY INTESTINAL DISEASES
EP1722834B1 (de) 2003-12-22 2012-06-27 Regentis Biomaterials Ltd. Matrix mit natürlich vorkommendem vernetztem proteingerüst
US7842667B2 (en) 2003-12-22 2010-11-30 Regentis Biomaterials Ltd. Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
EP1718664A4 (de) 2004-02-02 2008-08-13 Ambrx Inc Modifizierte menschliche vierhelix-bündel-peptide und ihre verwendungen
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1768700B1 (de) * 2004-07-16 2010-12-15 Nektar Therapeutics Konjugate enthaltend gm-csf und ein polymer
WO2009100255A2 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
JP2008507280A (ja) 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
WO2006015512A1 (en) * 2004-08-11 2006-02-16 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. A modified arginine deiminase
EP2586456B1 (de) 2004-10-29 2016-01-20 ratiopharm GmbH Umformung und GlycoPEGylierung des Fibroblastenwachstumsfaktors (FGF)
US7597907B2 (en) 2004-11-05 2009-10-06 Trustees Of The University Of Pennsylvania Antioxidant polymer nanocarriers for use in preventing oxidative injury
GB2438760A (en) 2004-12-22 2007-12-05 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
NZ584597A (en) 2004-12-22 2011-09-30 Ambrx Inc Modified human growth hormone
AU2005322019B2 (en) 2004-12-22 2010-08-26 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
NZ555425A (en) 2004-12-22 2010-04-30 Ambrx Inc Compositions of aminoacyl-tRNA synthetase and uses thereof
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
EP1871795A4 (de) 2005-04-08 2010-03-31 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
EP1891141B1 (de) 2005-05-31 2016-11-16 Ecole Polytechnique Fédérale de Lausanne (EPFL) Triblockcopolymere zur zytoplasmatischen zuführung von arzneistoffen auf genbasis
CN101247821B (zh) 2005-06-03 2013-01-23 Ambrx公司 经改良人类干扰素分子和其用途
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
CN102703446B (zh) 2005-08-18 2014-05-28 Ambrx公司 tRNA组合物和其用途
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007047922A2 (en) 2005-10-19 2007-04-26 Smartcells, Inc. Polymer-drug conjugates
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN106443006A (zh) 2005-11-16 2017-02-22 Ambrx公司 包括非天然氨基酸的方法和组合物
AU2007211829C9 (en) 2006-02-01 2013-07-11 Cephalon Australia Pty Ltd Domain antibody construct
JP2009534423A (ja) 2006-04-20 2009-09-24 アムジェン インコーポレイテッド Ｇｌｐ−１化合物
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
EP2054437A2 (de) 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin-fusionsproteine
AU2007292892B9 (en) 2006-09-08 2013-02-28 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
MX2009002523A (es) 2006-09-08 2009-03-20 Ambrx Inc Polipeptido de plasma humano modificado o andamios fc y sus usos.
NZ574960A (en) 2006-09-08 2012-02-24 Ambrx Inc Suppressor trna transcription in vertebrate cells
EP2698157B1 (de) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
ATE554785T1 (de) 2007-03-30 2012-05-15 Ambrx Inc Modifizierte fgf-21 polypeptide und ihre verwendung
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
NZ580030A (en) 2007-04-03 2012-06-29 Biogenerix Ag Methods of treatment using glycopegylated g-csf
EP2076533B1 (de) 2007-05-02 2014-10-08 Ambrx, Inc. Modifizierte interferon-beta-polypeptide und ihre verwendungen
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
US8568786B2 (en) 2007-10-27 2013-10-29 The Trustees Of The Universtiy Of Pennsylvania Method and compositions for polymer nanocarriers containing therapeutic molecules
US7927629B2 (en) 2007-10-27 2011-04-19 The Trustees Of The University Of Pennsylvania Method and compositions for polymer nanocarriers containing therapeutic molecules
CA2703830A1 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
CN103497246B (zh) 2008-02-27 2016-08-10 诺沃—诺迪斯克有限公司 缀合的因子viii分子
EP2260102A1 (de) 2008-03-25 2010-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
EP3225248B1 (de) 2008-07-23 2023-06-07 Ambrx, Inc. Modifizierte bovine g-csf-polypeptide und ihre verwendung
UA106731C2 (uk) 2008-09-26 2014-10-10 Амбркс, Інк. Модифіковані поліпептиди еритропоетину тварин та їх застосування
HUE036343T2 (hu) 2008-09-26 2018-07-30 Ambrx Inc Nem-természetes aminosav replikáció-függõ mikroorganizmusok és vakcinák
JP5814793B2 (ja) 2008-11-25 2015-11-17 エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル） ブロックコポリマーおよびその使用
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
EP2408808A4 (de) 2009-03-20 2015-05-06 Smartcells Inc Terminal-funktionalisierte konjugate und ihre verwendung
US8580732B2 (en) 2009-04-07 2013-11-12 Duke University Peptide therapy for hyperglycemia
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
US20120244170A1 (en) 2009-09-22 2012-09-27 Rafal Ciosk Treating cancer by modulating mex-3
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
EP3366695B1 (de) 2009-12-17 2021-07-07 Children's Medical Center Corporation Aus saposin-a gewonnene peptide und verwendungen davon
MX2012006980A (es) 2009-12-21 2012-07-17 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos.
JP2013515080A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているウシのソマトトロピンポリペプチドおよびそれらの使用
JP6148013B2 (ja) 2010-03-05 2017-06-14 リグショスピタレト 補体活性化のキメラ抑制分子
EP2542578A1 (de) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c und hirnkrebs
EP2561076A1 (de) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulation von xrn1
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
US20120135912A1 (en) 2010-05-10 2012-05-31 Perseid Therapeutics Llc Polypeptide inhibitors of vla4
EP2580239A1 (de) 2010-06-10 2013-04-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krebs mittels modulation von mammalian-ste20-like-kinase 3
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
BR112013003522B1 (pt) 2010-08-17 2021-05-25 Ambrx, Inc. polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
US20140093506A1 (en) 2010-11-15 2014-04-03 Marc Buehler Anti-fungal-agents
EP2474612A1 (de) 2011-01-05 2012-07-11 University College Dublin, National University of Ireland Dublin Affinitätstrennungsmittel und ihre Verwendungen zur Trennung, Reinigung und Konzentration von Zielmolekülen
US9181553B2 (en) 2011-06-06 2015-11-10 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Method of treatment of breast cancers over-expressing the SHP2 signature genes
AR087020A1 (es) 2011-07-01 2014-02-05 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos
EP2776022A1 (de) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Neue behandlung für neurodegenerative erkrankungen
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
EP3560509B1 (de) 2011-12-22 2024-01-31 Children's Medical Center Corporation Aus saposin-a gewonnene peptide und verwendungen davon
US20140363448A1 (en) 2012-01-02 2014-12-11 Novartis Ag Cdcp1 and breast cancer
US9474810B2 (en) * 2012-03-02 2016-10-25 General Electric Company Superparamagnetic nanoparticles with PEG substituted α-hydroxy phosphonate shells
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
EP2831112A1 (de) 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Hemmung von interleukin 8 und/oder dessen rezeptor cxcrl bei der behandlung von brustkrebs mit her2/her3-überexpression
GB2516388A (en) 2012-04-16 2015-01-21 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
EP2866831A1 (de) 2012-06-29 2015-05-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krankheiten durch modulation einer spezifischen isoform von mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
SI3584255T1 (sl) 2012-08-31 2022-05-31 Sutro Biopharma, Inc Modificirane aminokisline, ki vsebujejo azido skupino
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US10711106B2 (en) 2013-07-25 2020-07-14 The University Of Chicago High aspect ratio nanofibril materials
EP3030902B1 (de) 2013-08-07 2019-09-25 Friedrich Miescher Institute for Biomedical Research Neues screening-verfahren zur behandlung von friedreich-ataxie
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CN104007079B (zh) * 2014-04-18 2016-06-29 深圳赛保尔生物药业有限公司 重组人促红素聚乙二醇化反应液的光谱检测法及应用
WO2015189816A1 (en) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research New treatment against influenza virus
WO2015198202A1 (en) 2014-06-23 2015-12-30 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
US20170298360A1 (en) 2014-09-24 2017-10-19 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
WO2016065326A2 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
CA2994971A1 (en) 2015-08-12 2017-02-16 Cell Machines, Inc. Methods and compositions related to long half-life coagulation complexes
WO2017072669A1 (en) 2015-10-28 2017-05-04 Friedrich Miescher Institute For Biomedical Research Tenascin-w and biliary tract cancers
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US20200216563A1 (en) 2017-08-10 2020-07-09 Friedrich Miescher Institute For Biomedical Research Hdac6 and protein aggregation
EP3849614B1 (de) 2018-09-11 2023-12-20 Ambrx, Inc. Interleukin-2-polypeptidkonjugate und deren verwendungen
EP3867265A1 (de) 2018-10-19 2021-08-25 Ambrx, Inc. Interleukin-10 -polypeptid-konjugate, dimere davon und ihre verwendungen
MX2021009644A (es) 2019-02-12 2021-09-08 Ambrx Inc Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr.
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
TW202227449A (zh) 2020-08-20 2022-07-16 美商Ａｍｂｒｘ 公司 抗體－ｔｌｒ促效劑偶聯物、其方法及用途
US20250161471A1 (en) 2021-04-03 2025-05-22 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
CN114230739B (zh) * 2021-12-14 2023-08-11 西安交通大学 一种线性-非线性嵌段聚合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4912599B1 (de) * 1970-07-02 1974-03-26
WO1985003934A1 (fr) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
GB8824593D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
GB8824592D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Purification process
JP2997004B2 (ja) * 1989-05-26 2000-01-11 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
AU5006993A (en) * 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
WO1994023726A1 (en) * 1993-04-22 1994-10-27 Mallinckrodt Medical, Inc. Calmodulin blocking agent adducts useful as anti-platelet agents
GB9317618D0 (en) * 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5686110A (en) * 1994-06-02 1997-11-11 Enzon, Inc. Water soluble complex of an alkyl or olefinic end capped polyalkylene oxide and a water insoluble substance
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods

Also Published As

Publication number Publication date
DE69800640T2 (de) 2001-07-05
JP2001508783A (ja) 2001-07-03
EP0921817B1 (de) 2001-03-28
WO1998032466A1 (en) 1998-07-30
AU5773798A (en) 1998-08-18
DE69800640D1 (en) 2001-05-03
EP0921817A1 (de) 1999-06-16

Similar Documents

Publication Publication Date Title
ATE200030T1 (de) Pegylationsverfahren
ATE263157T1 (de) Nematizide trifluorbutene
EP0528858A4 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
WO1998011900A3 (en) Compositions containing cobalamin and amino acids
TW289020B (de)
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
LU91204I2 (fr) Pegvisomant, facultativement sous forme d'une variante de pégylation
EP1391536A3 (de) Zusammensetzung und Verfahren zur Plattierung von Silber auf ein metallisches Substrat
WO1999064047A8 (en) Novel antiviral compounds
AU7998291A (en) Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
ATE360706T1 (de) Peptidakzeptor ligationsverfahren
GB0011203D0 (en) Chemical compounds
ITRM940018A0 (it) Procedimento per la preparazione di polimeri ammina-aldeide contenentigruppi solfo, polimeri ottenuti secondo questo procedimento e loro impiego. (caso 154-0238)
CY1106978T1 (el) Ενζυμα φωσφοδιεστερασης
PT882726E (pt) Carbazol-carboxamidas como agonistas 5-ht1f
DK50687D0 (da) Oe2,2-bis-(aminomethyl)-1,3-propandiol-n,n'aa-pla- tinkomplekser
ES2109418T3 (es) Procedimiento para la preparacion de polimeros a base de monoxido de carbono y olefinas.
CO4950549A1 (es) Procedimiento
BR0010934A (pt) Peptìdeos n-alquilados possuindo atividade antiangiogênica
DE3878301D1 (de) Desinfizierende polymerbeschichtungen fuer harte oberflaechen.
BR0114884A (pt) Compostos calcilìticos
DE3765765D1 (de) Polymere als beizmittel fuer saure farbstoffe.
TR200002755T2 (tr) Aracı hazırlamak için süreç.
CZ123495A3 (en) Process for preparing 2-amino-4,6-dichloropyrimidine
CY1106051T1 (el) ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΓΩΓΗ Ν-ΠΡΟΣΤΑΤΕΥΜΕΝΩΝ ΑΖΕΤΙΔΙΝΟ-2-ΚΑΡΒΟΞΥΛΙΚΩΝ ΟΞΕΩΝ (AzeOHs)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties